The bm|t is pleased to announce that seven of its Investee Part\u00adners have already closed fund\u00ading rounds in 2018. Over \u20ac10 mil\u00adlion has been raised by Biano GMP, ifesca, JenID, Mas\u00adter\u00adPIM, OnCG\u00adnos\u00adtics, Pre\u00adven\u00adti\u00adcus and SiOp\u00adtica. The money secures funds for impor\u00adtant and value-adding fur\u00adther developments.
\nThese invest\u00adment rounds con\u00adtinue the momen\u00adtum from 2017, which saw over \u20ac150 mil\u00adlion invested in 21 port\u00adfo\u00adlio com\u00adpa\u00adnies. Kevin Reeder, CEO of bm|t, sees the con\u00adtin\u00adu\u00ada\u00adtion of the fundrais\u00ading as a great sig\u00adnal for Thuringia and a strong sig\u00adnal to investors to show the attrac\u00adtive\u00adness of invest\u00ading in the region. \u201cWith two very suc\u00adcess\u00adful and highly pub\u00adli\u00adcised exits last year \u2014 a sale to Face\u00adbook and a Nas\u00addaq IPO, bm|t has appeared on the radar screens of many investors. We see a grow\u00ading inter\u00adest in co-invest\u00adments together with bm|t here in Thuringia, which will greatly help us catal\u00adyse the next Thuringian champions.\u201d
\nOf par\u00adtic\u00adu\u00adlar note, two of the 2018 financ\u00adings drew sev\u00aderal mil\u00adlion euros from out\u00adside Ger\u00admany, with one invest\u00adment com\u00ading from Switzer\u00adland and another from Bel\u00adgium. \u201cWe know that our com\u00adpa\u00adnies have pow\u00ader\u00adful inno\u00adva\u00adtions and great sub\u00adstance, and we are pleased that other investors out\u00adside Ger\u00admany have recog\u00adnised this and will work with us as co-investors to move these com\u00adpa\u00adnies for\u00adward,\u201d Reeder said.<\/p>\n
BianoGMP GmbH was founded in August 2017 with the aim of estab\u00adlish\u00ading itself as a GMP ser\u00advice provider for medium to small batch sizes in the growth seg\u00adment of oligonu\u00adcleotides, thereby low\u00ader\u00ading the bar\u00adri\u00aders for poten\u00adtial cus\u00adtomers to enter pre\u00adclin\u00adi\u00adcal and clin\u00adi\u00adcal devel\u00adop\u00adment. In addi\u00adtion, inno\u00adv\u00ada\u00adtive new and fur\u00adther devel\u00adop\u00adments in related ser\u00advices are planned in order to offer cus\u00adtomers the broad\u00adest pos\u00adsi\u00adble spec\u00adtrum around GMP-com\u00adpli\u00adant nucleotide pro\u00adduc\u00adtion from a sin\u00adgle source. Founded in 2016 in Ilme\u00adnau, ifesca offers deci\u00adsion sup\u00adport solu\u00adtions and ser\u00advices based on arti\u00adfi\u00adcial intel\u00adli\u00adgence for the energy mar\u00adket. High-qual\u00adity fore\u00adcasts for energy-related time series and opti\u00admised oper\u00ada\u00adtions for energy gen\u00ader\u00ada\u00adtion are pro\u00advided by the spe\u00adcialised IoT plat\u00adform ifesca.AIVA. ifesca\u2019s \u201cas a ser\u00advice\u201d solu\u00adtions mas\u00adsively help auto\u00admate deci\u00adsion-mak\u00ading processes, thereby increas\u00ading fore\u00adcast qual\u00adity and reduc\u00ading man\u00adual effort and process com\u00adplex\u00adity. The ser\u00advices are pro\u00advided to every par\u00adtic\u00adi\u00adpant in the global energy mar\u00adkets. Work\u00ading in these mar\u00adkets for over 15 years and hav\u00ading a sci\u00aden\u00adtific back\u00adground enables the ifesca team to develop its unpar\u00adal\u00adleled AI solutions. jenID Solu\u00adtions pro\u00advides flex\u00adi\u00adble soft\u00adware solu\u00adtions for cus\u00adtomers in finan\u00adcial ser\u00advices, insur\u00adance, car rental, telecom\u00admu\u00adni\u00adca\u00adtions and other indus\u00adtries, tai\u00adlored to their needs and enabling them to per\u00adform secure, real-time iden\u00adtity ver\u00adi\u00adfi\u00adca\u00adtion any\u00adwhere in the world. The com\u00adpany thus knows who is access\u00ading, using or bor\u00adrow\u00ading its prod\u00aducts. The jenID thus helps pro\u00adtect the iden\u00adtity of end users and pre\u00advents fraud. Mas\u00adter\u00adPIM devel\u00adops a browser-based tool for straight\u00adfor\u00adward prod\u00aduct infor\u00adma\u00adtion man\u00adage\u00adment (PIM). The mod\u00adu\u00adlar struc\u00adture enables the map\u00adping of sim\u00adple data con\u00adver\u00adsion up to a fully scal\u00adable enter\u00adprise solu\u00adtion for retail\u00aders and man\u00adu\u00adfac\u00adtur\u00aders, with\u00adout large project man\u00adage\u00adment, with\u00adout lengthy inte\u00adgra\u00adtion processes. Mas\u00adter PIM delib\u00ader\u00adately avoids fea\u00adture-dri\u00adven onboard\u00ading processes and instead relies on prag\u00admatic, stan\u00addard\u00adised out-of-the-box solutions. oncg\u00adnos\u00adtics GmbH was founded in 2012 as a spin-off from a uni\u00adver\u00adsity research group at the Uni\u00adver\u00adsity Wom\u00aden\u2019s Hos\u00adpi\u00adtal in Jena. As a mol\u00ade\u00adc\u00adu\u00adlar diag\u00adnos\u00adtics com\u00adpany, the Jena-based start-up spe\u00adcialises in the diag\u00adno\u00adsis of can\u00adcer. The tests detect char\u00adac\u00adter\u00adis\u00adtic epi\u00adge\u00adnetic changes, so-called DNA methy\u00adla\u00adtions, in can\u00adcer cells. The bio\u00admark\u00aders, iden\u00adti\u00adfied and patented with a spe\u00adcial algo\u00adrithm, form the core of the prod\u00aducts and are the basis of the company. Pre\u00adven\u00adti\u00adcus turns a smart\u00adphone into a med\u00adical mea\u00adsur\u00ading tool. This makes it pos\u00adsi\u00adble for users to carry out pre\u00advi\u00adously com\u00adplex pre\u00adven\u00adtive exam\u00adi\u00adna\u00adtions at home via smart\u00adphone and to main\u00adtain their own health through pre\u00adcisely tai\u00adlored pre\u00adven\u00adtive mea\u00adsures. The USP of Pre\u00adven\u00adti\u00adcus are supe\u00adrior biosig\u00adnal-ana\u00adlyt\u00adi\u00adcal algo\u00adrithms with high clin\u00adi\u00adcal evi\u00addence, which enable risk screen\u00ading via smart\u00adphone. Indi\u00advid\u00adual pre\u00adven\u00adtion mea\u00adsures are derived from the health pro\u00adfile, their effect is mon\u00adi\u00adtored and users are con\u00adnected with health partners. The com\u00adpany was founded in Jena in 2013 with the aim of estab\u00adlish\u00ading inno\u00adv\u00ada\u00adtive and spe\u00adcialised solu\u00adtions in the mar\u00adket, espe\u00adcially in the field of optics. The com\u00adpany offers tech\u00adnolo\u00adgies in the field of pri\u00advacy fil\u00adters that can pro\u00adtect screen data from unau\u00adtho\u00adrised view with\u00adout caus\u00ading bright\u00adness loss and can be oper\u00adated in pub\u00adlic or pri\u00advate modes. SiOp\u00adti\u00adca\u2019s solu\u00adtions offer great ben\u00ade\u00adfits in the ATM \/ bank\u00ading, retail \/ pay\u00adment ter\u00admi\u00adnal, logis\u00adtics \/ secure access, data secu\u00adrity and con\u00adsumer elec\u00adtron\u00adics sectors. The Erfurt-based bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment Th\u00fcrin\u00adgen (bm|t) \u2014 a sub\u00adsidiary of the Th\u00fcringer Auf\u00adbaubank \u2014 is the first port of call for invest\u00adments in Thuringia. Cur\u00adrently, bm|t man\u00adages eight invest\u00adment funds with a total vol\u00adume of \u20ac 320 mil\u00adlion. bm|t invests in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies with strong growth poten\u00adtial across all sec\u00adtors and all phases of the com\u00adpany life cycle. The bm|t is pleased to announce that seven of its Investee Part\u00adners have already closed fund\u00ading rounds in 2018. Over \u20ac10 mil\u00adlion has been raised by Biano GMP, ifesca, JenID, Mas\u00adter\u00adPIM, OnCG\u00adnos\u00adtics, Pre\u00adven\u00adti\u00adcus and SiOp\u00adtica. The money secures funds for impor\u00adtant and value-adding fur\u00adther devel\u00adop\u00adments. These invest\u00adment rounds con\u00adtinue the momen\u00adtum from 2017, which saw [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[147],"tags":[],"class_list":["post-11617","post","type-post","status-publish","format-standard","hentry","category-2018-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=11617"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11617\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=11617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=11617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=11617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nFur\u00adther infor\u00adma\u00adtion on BianoGMP can be found at: bianoscience.com\/GMP_Oligonucleotides.<\/a><\/p>\nAbout ifesca<\/h3>\n
\nFor more infor\u00adma\u00adtion on ifesca, please visit: www.ifesca.de<\/a> ifesca-aiva.com\/<\/a><\/p>\nAbout jenID<\/h3>\n
\nFor more infor\u00adma\u00adtion on jenID Solu\u00adtions, please visit: www.jenidsolutions.com<\/a><\/p>\nAbout MasterPIM<\/h3>\n
\nFor more infor\u00adma\u00adtion on Mas\u00adter\u00adPIM, please visit: http:\/\/www.masterpim.de\/<\/a><\/p>\nAbout Oncgnostics<\/h3>\n
\nFor more infor\u00adma\u00adtion about oncg\u00adnos\u00adtics, please visit: http:\/\/www.oncgnostics.com\/<\/a>.<\/p>\nAbout Preventicus<\/h3>\n
\nFor more infor\u00adma\u00adtion about Pre\u00adven\u00adti\u00adcus, please visit: http:\/\/www.preventicus.com\/<\/a><\/p>\nAbout SiOptica<\/h3>\n
\nFor more infor\u00adma\u00adtion about SiOp\u00adtica, please visit: www.sioptica.com<\/a><\/p>\nAbout bm\u2011t<\/h3>\n
\nFur\u00adther infor\u00adma\u00adtion on bm|t can be found at: www.bm\u2011t.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"